###begin article-title 0
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 68 75 68 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 20 24 <span type="species:ncbi:10090">Mice</span>
The Use of Knockout Mice Reveals a Synergistic Role of the Vav1 and Rasgrf2 Gene Deficiencies in Lymphomagenesis and Metastasis
###end article-title 0
###begin p 1
Conceived and designed the experiments: SR XRB. Performed the experiments: SR. Analyzed the data: SR ES XRB. Contributed reagents/materials/analysis tools: ES. Wrote the paper: SR XRB.
###end p 1
###begin p 2
Current address: Gene Expression Lab, The Salk Institute for Biological Studies, La Jolla, California, United States of America
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
Vav1 and RasGRF2 are GDP/GTP exchange factors for Ras superfamily GTPases with roles in the development and/or effector functions of T-lymphocytes.
###end p 4
###begin title 5
Methodology/Principal Findings
###end title 5
###begin p 6
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 32 35 32 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 37 44 37 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 44 47 44 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 56 59 56 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 67 70 67 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 287 291 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 550 551 550 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 683 690 683 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
###xml 375 379 <span type="species:ncbi:10090">mice</span>
Given that the phenotype of Vav1-/-, Rasgrf2-/- and Vav1-/-;Rasgrf2-/- mice has been studied so far in young animals, we decided to explore the long-term consequences of the inactivation of those loci in the immune system. Unexpectedly, our studies revealed that the inactivation of the Vav1 proto-oncogene favors the formation of lymphoblastic lymphoma-like tumors in aging mice. Those tumors, that can be found either localized exclusively inside the thymus or widely disseminated in hematopoietic and non-hematopoietic tissues, are composed of CD3+ lymphoblasts that display heterogeneous combinations of CD4 and CD8 surface markers. Interestingly, the additional deletion of the Rasgrf2 gene induces a shortening in the latency period for the development of those tumors, an increase in the percentage of disseminated tumors outside the thymus and, as a result, higher mortality rates.
###end p 6
###begin title 7
Conclusions/Significance
###end title 7
###begin p 8
###xml 285 292 285 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
These data reveal unexpected negative roles for Vav1 and RasGRF2 in different stages of T-cell lymphoma progression. They also suggest that the inactivation of Vav1 function may represent an inadequate strategy to treat T-cell lymphomas, especially those associated with low levels of Rasgrf2 gene expression.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 243 246 243 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Colicelli1">[1]</xref>
###xml 247 250 247 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Barbacid1">[6]</xref>
###xml 735 738 735 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Bos1">[7]</xref>
###xml 900 903 900 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Bos1">[7]</xref>
###xml 1141 1144 1141 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Dransart1">[8]</xref>
###xml 1145 1149 1145 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Olofsson1">[10]</xref>
###xml 1483 1486 1483 1486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Colicelli1">[1]</xref>
###xml 1488 1491 1488 1491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Lowy1">[5]</xref>
###xml 1493 1496 1493 1496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Barbacid1">[6]</xref>
Ras and Rho/Rac proteins play essential roles in normal signal transduction and pathological states, since they activate intracellular pathways that impinge directly in biological processes related to cell proliferation, survival and motility [1]-[6]. Under normal conditions, these proteins cycle between an inactive, GDP-bound state and an active, GTP-bound conformation. The cycling between these two conformations is regulated by GDP/GTP exchange factors (GEFs), GTPase activating proteins (GAPs) and, in some cases, by Rho GDP dissociation inhibitors (RhoGDIs). GEFs promote the rapid exchange of GDP by GTP during cell signaling, thereby helping the rapid transition of Ras and Rho/Rac GTPases from the inactive to active states [7]. GAP proteins enhance the hydrolysis rates of bound GTP molecules, thus favoring the inactivation of Ras and Rho/Rac GTPases at the end of the stimulation cycle [7]. Finally, RhoGDIs contribute to the downmodulation of Rho/Rac-dependent GTPase pathways by retrieving the GTPases from membranes and, subsequently, by maintaining them sequestered in the cytosol in their inactive, GDP-bound conformation [8]-[10]. The importance of this regulatory cycle is underscored by the observation that point mutations affecting either GTP hydrolysis or the intrinsic GDP/GTP exchange of Ras and Rho/Rac proteins lead to the generation of GTPases with high (in the case of Ras GTPases) or intermediate (in the case of Rho/Rac proteins) oncogenic potential [1], [5], [6].
###end p 10
###begin p 11
###xml 519 523 519 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Lin1">[11]</xref>
###xml 580 587 580 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 770 774 770 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Qiu1">[12]</xref>
###xml 775 779 775 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Jacinto1">[15]</xref>
###xml 1047 1051 1047 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Jacinto1">[15]</xref>
###xml 1579 1583 1579 1583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 1592 1599 1592 1599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRP1</italic>
###xml 1654 1658 1654 1658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 1668 1675 1668 1675 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRP1</italic>
###xml 1772 1776 1772 1776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Katzav1">[16]</xref>
###xml 1778 1782 1778 1782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Tognon1">[17]</xref>
###xml 591 596 <span type="species:ncbi:9606">human</span>
###xml 1573 1578 <span type="species:ncbi:9606">human</span>
Whereas it has been always assumed that tumorigenic processes could be positively and negatively regulated by GEFs and GAPs/RhoGDIs, respectively, recent data have revealed that this regulatory picture is more complex than initially anticipated. For example, it has been recently shown that RhoGDIs are required for the efficient transforming activity of the GTPase Cdc42, an observation that suggest that these GTPase inhibitors may also play positive roles in the translocation and/or effector phase of these GTPases [11]. On the other hand, recent observations have shown that RASGRF2, a human gene encoding a dual GEF with specificity for Ras and Rho/Rac proteins, is either hypermethylated or downregulated transcriptionally in cancer cell lines and primary tumors [12]-[15], a biological property reminiscent of genes associated with tumor suppressor activities. Consistent with this possibility, it has been recently demonstrated that the overexpression of RasGRF2 affects negatively the transforming properties of a colon cancer cell line [15]. Despite the above results, there is no actual evidence indicating that this GEF could play tumor suppressor-like activities in tumorigenic processes in vivo. Likewise, we have no information regarding the implication of other GEFs in the negative regulation of tumor growth. In fact, the overexpression of wild type or the expression of constitutively-active mutant versions of many GEFs have been usually associated to oncogenesis rather than to growth inhibitory signals. For example, the transforming activity of the human VAV1 and the RASGRP1 oncogenes, two loci encoding GEFs for either Rho/Rac (VAV1) or Ras (RASGRP1), was the biological read-out that allowed the discovery of these important regulatory proteins [16], [17].
###end p 11
###begin p 12
###xml 334 338 330 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Ruiz1">[18]</xref>
###xml 430 437 426 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 518 522 514 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 522 525 518 521 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 534 538 530 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Ruiz1">[18]</xref>
###xml 619 623 615 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 623 626 619 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 628 635 624 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 635 638 631 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 640 644 636 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 644 647 640 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 648 655 644 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 655 658 651 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 831 835 827 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 840 847 836 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 424 429 <span type="species:ncbi:10090">mouse</span>
###xml 939 943 <span type="species:ncbi:10090">mice</span>
Recently, we described that the Vav1 and RasGRF2 GEFs play synergistic roles in the activation of specific T-cell receptor (TCR) downstream signaling pathways, including the optimal activation of phospholipase C-gamma, the stimulation of the nuclear factor of activated T-cells, and the transcriptional upregulation of cytokine genes [18]. Consistent with this signaling cross-talk, we demonstrated that the deletion of the mouse Rasgrf2 gene aggravated the defective proliferative responses of mature, TCR-stimulated Vav1-/- T-cells [18]. Given the aforementioned defects, we decided to perform long-term studies with Vav1-/-, Rasgrf2-/-, Vav1-/-;Rasgrf2-/- and control animals to investigate the possible development of additional, age-dependent immune defects such as autoimmune disease. Unexpectedly, we found that the loss of Vav1 and Rasgrf2 genes cooperated synergistically in the development of very aggressive T-cell lymphomas in mice. These observations indicate that in some specific signaling contexts, the absence of GEF function may contribute to, rather than impacting negatively on, tumorigenesis. They also suggest that anti-cancer therapies directed against GEFs may not be advisable in some tumor types.
###end p 12
###begin title 13
Results
###end title 13
###begin title 14
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 31 38 31 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
Synergistic Effect of Vav1 and Rasgrf2 Gene Deficiencies in Leukemia/Lymphoma Development
###end title 14
###begin p 15
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 34 37 34 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 39 46 39 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 46 49 46 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 58 61 58 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1<sup>&#8211;/&#8211;</sup></italic>
###xml 62 69 62 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 69 72 69 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 420 421 420 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 432 439 432 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 439 442 439 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 449 450 449 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 522 525 522 525 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 518 525 518 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1<sup>&#8211;/&#8211;</sup></italic>
###xml 540 541 540 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 584 588 584 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 588 591 588 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 592 599 592 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 599 602 599 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 616 617 616 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 693 702 693 702 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 693 702 693 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g001"><bold>Figure 1A</bold></xref>
###xml 770 774 770 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 774 777 774 777 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 778 785 778 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 785 788 785 788 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 825 834 825 834 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 825 834 825 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g001"><bold>Figure 1A</bold></xref>
###xml 1168 1177 1168 1177 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 1168 1177 1168 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g001"><bold>Figure 1B</bold></xref>
###xml 1596 1605 1596 1605 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1C</bold>
###xml 1596 1637 1596 1637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g001"><bold>Figure 1C</bold>, compare upper and lower panels</xref>
###xml 1708 1717 1708 1717 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1C</bold>
###xml 1708 1717 1708 1717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g001"><bold>Figure 1C</bold></xref>
###xml 1727 1736 1727 1736 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1C</bold>
###xml 1727 1736 1727 1736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g001"><bold>Figure 1C</bold></xref>
###xml 1746 1755 1746 1755 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1C</bold>
###xml 1746 1755 1746 1755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g001"><bold>Figure 1C</bold></xref>
###xml 1892 1896 1892 1896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav2</italic>
###xml 1896 1899 1896 1899 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1901 1905 1901 1905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav3</italic>
###xml 1905 1908 1905 1908 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1912 1916 1912 1916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav2</italic>
###xml 1916 1919 1916 1919 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1920 1924 1920 1924 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav3</italic>
###xml 1924 1927 1924 1927 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1971 1972 1971 1972 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2045 2049 2045 2049 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 2153 2160 2153 2160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
###xml 304 309 <span type="species:ncbi:10090">mouse</span>
###xml 603 607 <span type="species:ncbi:10090">mice</span>
###xml 789 793 <span type="species:ncbi:10090">mice</span>
###xml 1928 1932 <span type="species:ncbi:10090">mice</span>
###xml 2079 2083 <span type="species:ncbi:10090">mice</span>
Given the defects observed in Vav1-/-, Rasgrf2-/- and Vav1-/-;Rasgrf2-/- mice in TCR-mediated responses, we decided to perform long-term studies with those animals to investigate the possible development of additional, age-dependent immune defects. To avoid interferences with genetic polymorphisms, all mouse strains were previously homogenized in the B10.BR genetic background. We observed that whereas wild type (6%, n = 32) and Rasgrf2-/- (12%, n = 24) animals showed a low disease/death rate up to a year of age, Vav1-/- animals (32%, n = 25) and, to a larger extent, the double Vav1-/-;Rasgrf2-/- mice (68.6%, n = 42) were prone to either dying prematurely or falling sick as they aged (Figure 1A). The latency periods for disease development were also shorter in Vav1-/-;Rasgrf2-/- mice than in the rest of genotypes (Figure 1A). Unexpectedly, the examination of dead and euthanized sick animals indicated that the disease/death cause was the presence of highly disseminated lymphoid tumors rather than any type of autoimmune disease. Specifically, we observed hyperplasia of thymi, massive splenomegalies and lymphadenopathies in most of the animals analyzed (Figure 1B). The above tissues also showed a disruption of their normal histological structures as a consequence of the extensive growth and/or colonization of the whole tissue by tumor cells. Due to this, the typical separation of cortical and medullar areas, the white and red pulp areas, and the germinal/peripheral centers where completely blurred or eliminated in the thymi, spleen and mesenteric lymph nodes, respectively (Figure 1C, compare upper and lower panels). We also detected extensive infiltrations of tumor cells in kidneys (Figure 1C), lungs (Figure 1C), liver (Figure 1C), intestine (data not shown), and bone marrow (see below). Interestingly, we did not find increased rates of leukemia/lymphoma in aging Vav2-/-, Vav3-/- or Vav2-/-;Vav3-/- mice when compared to control littermates (n>30 for each genotype, data not shown). These results indicated that the Vav1 proto-oncogene deficiency in mice leads in the long-term to leukemia/lymphoma and that the loss of the Rasgrf2 gene further accentuates the progression of that disease.
###end p 15
###begin title 16
###xml 13 25 13 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1/Rasgrf2</italic>
The combined Vav1/Rasgrf2 gene deficiency enhances the rates of lymphomas.
###end title 16
###begin p 17
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 158 159 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 170 171 170 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 179 180 179 180 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 261 265 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 265 268 265 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 269 276 269 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 276 279 276 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 304 305 304 305 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 441 445 441 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 445 448 445 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 449 456 449 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 456 459 456 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
###xml 474 479 <span type="species:ncbi:10090">mouse</span>
(A) Kaplan-Meyer distribution graph showing the percentage of survival rates of mice of the indicated genotypes. NS, non-statistically significant values; *, P<0.01; **, P<0.05. (B) Examples of non-tumorigenic (NT) and tumorigenic (T) tissues obtained from two Vav1-/-;Rasgrf2-/- mice. Scale bar, 1 cm. (C) Hematoxylin/eosin stained sections of healthy and tumoral tissues obtained from a healthy wild type (upper panel) and a tumor-bearing Vav1-/-;Rasgrf2-/- (lower panel) mouse, respectively. Scale bar, 100 microm. Asterisks, tumoral cells infiltrates in non-hematopoietic tissues.
###end p 17
###begin title 18
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 42 45 42 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 46 53 46 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 53 56 53 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 57 61 <span type="species:ncbi:10090">Mice</span>
Characterization of Tumors Present in Vav1-/-;Rasgrf2-/- Mice
###end title 18
###begin p 19
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 103 106 103 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 107 114 107 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 114 117 114 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 122 126 122 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 126 129 126 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 254 263 254 263 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2A</bold>
###xml 254 263 254 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g002"><bold>Figure 2A</bold></xref>
###xml 425 434 425 434 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2A</bold>
###xml 425 434 425 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g002"><bold>Figure 2A</bold></xref>
###xml 655 664 655 664 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2B</bold>
###xml 655 664 655 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g002"><bold>Figure 2B</bold></xref>
###xml 881 890 881 890 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2C</bold>
###xml 881 901 881 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g002"><bold>Figure 2C</bold>, animal #1</xref>
###xml 975 976 975 976 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 979 980 979 980 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 988 989 988 989 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1003 1012 1003 1012 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2C</bold>
###xml 1003 1023 1003 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g002"><bold>Figure 2C</bold>, animal #2</xref>
###xml 1055 1056 1055 1056 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1107 1116 1107 1116 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2C</bold>
###xml 1107 1127 1107 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g002"><bold>Figure 2C</bold>, animal #3</xref>
###xml 1312 1313 1312 1313 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1336 1337 1336 1337 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1539 1548 1539 1548 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2C</bold>
###xml 1539 1548 1539 1548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g002"><bold>Figure 2C</bold></xref>
Flow cytometry analysis of cells obtained from the thymus, spleen and bone marrow of tumor-bearing Vav1-/-;Rasgrf2-/- and Vav1-/- animals revealed the presence of a new population characterized by the surface expression of CD3, a T-cell specific marker (Figure 2A). The percentage of cells belonging to this population was highly variable among the animals under study (12-90%, see an example by comparing the left panels of Figure 2A). Consistent with these cytometry data, immunohistochemical analysis of tissue sections indicated that the tumor cells present in both hematopoietic and non-hematopoietic tissues displayed high levels of CD3 expression (Figure 2B). By contrast, these tumor cells were more heterogeneous in terms of the surface expression of the CD4 and CD8 markers. Thus, we found cases in which tumor cells were homogeneously double positive for those markers (Figure 2C, animal #1), cases in which the leukemia/lymphomas were composed of two separate CD4+CD8+ and CD8+ populations (Figure 2C, animal #2), and cases in which single CD8+ cells were observed in the tumor cell population (Figure 2C, animal #3). Although the distributions of the CD4 and CD8 markers were rather stochastic in the tumor cells analyzed, we did find that single positive T-cells were usually skewed towards the CD8+ rather than to the CD4+ lineage. Despite this variability among animals, the surface immunophenotype of the leukemia/lymphoma cells from the same animal was similar independently of the tissue source they were obtained from (Figure 2C).
###end p 19
###begin title 20
Characterization of lymphoid tumors.
###end title 20
###begin p 21
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 213 214 213 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 302 303 302 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 380 381 380 381 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 412 416 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 416 419 416 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 420 427 420 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 427 430 427 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 744 745 740 741 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 817 821 813 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 821 824 817 820 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 825 832 821 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 832 835 828 831 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 925 926 921 922 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1009 1013 1005 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 1013 1016 1009 1012 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1017 1024 1013 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 1024 1027 1020 1023 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1096 1097 1092 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 1102 1103 1098 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 1354 1355 1350 1351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 431 436 <span type="species:ncbi:10090">mouse</span>
###xml 664 669 <span type="species:ncbi:10090">mouse</span>
###xml 1028 1032 <span type="species:ncbi:10090">mice</span>
(A) Cell suspensions from healthy and tumoral tissues obtained from mice of the indicated genotypes (right) were stained with anti-CD3 antibodies and subjected to flow cytometry analysis. Red squares highlight CD3+ positive cell populations present in the animals under study. The percentage of the CD3+ population in each case is indicated inside each panel. SSC, side scatter. (B) Tissues from a tumor-bearing Vav1-/-;Rasgrf2-/- mouse (panels 3-7 counting from the left) were stained with either anti-CD3 (top panels) or anti-PCNA (bottom panels) using immunohistochemistry techniques. As control, we stained thymus and spleen sections obtained from a wild type mouse (first and second panel from left, respectively). Scale bar, 100 microm. (C) Cell suspensions were isolated from a healthy and three tumor-bearing Vav1-/-;Rasgrf2-/- animals, stained with anti-CD4 and anti-CD8 antibodies, and analyzed by flow cytometry. (D) Cell suspensions derived from the indicated tissues of a healthy and two tumoral Vav1-/-;Rasgrf2-/- mice were collected and blasts visualized by flow cytometry. In the y and x axes, the SSC and FCS values range from 0 to 1,024, respectively. The vertical lines indicate the FCS point from where gated cells were considered as blasts. FCS, forward scatter. The percentage of blasts in each case is indicated inside each panel. n = 5 and 10 for healthy and tumor-bearing animals, respectively (panels A-D).
###end p 21
###begin p 22
###xml 236 245 236 245 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2D</bold>
###xml 236 245 236 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g002"><bold>Figure 2D</bold></xref>
###xml 533 542 529 538 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2B</bold>
###xml 533 542 529 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g002"><bold>Figure 2B</bold></xref>
###xml 544 548 540 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Moldovan1">[19]</xref>
###xml 823 827 819 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Sancho1">[20]</xref>
###xml 1006 1010 1002 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 1010 1013 1006 1009 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1015 1022 1011 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 1022 1025 1018 1021 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
We next investigated the proliferative status of the leukemia/lymphoma cells present in these animals. Flow cytometry analyses indicated that tumor cells contained large percentages of blasts, an indication of high proliferative rates (Figure 2D). Immunohistochemistry experiments confirmed these results, since all tumors sections analyzed displayed higher expression levels of the proliferating cell nuclear antigen (PCNA), a processivity factor for DNA polymerase delta whose expression correlates with active cell proliferation (Figure 2B) [19]. Despite this, we could not observe any increase in the expression of the surface marker CD69 in thymic, splenic, or bone-marrow derived leukemia/lymphoma cells by flow cytometry (data not shown). Since CD69 is upregulated in proliferating T-cells in a TCR-dependent manner [20], these results suggest that the proliferation of those leukemia/lymphoma cells occurs independently of TCR engagement. Similar data were obtained with tumors derived from single Vav1-/-, Rasgrf2-/- and wild type animals.
###end p 22
###begin title 23
Thymic Origin of Tumors
###end title 23
###begin p 24
###xml 217 221 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 221 224 221 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 226 233 226 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 233 236 233 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 241 245 241 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 245 248 245 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 249 256 249 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 256 259 256 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 689 690 689 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 736 743 736 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 743 746 743 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 817 826 817 826 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 817 826 817 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g003"><bold>Figure 3A</bold></xref>
###xml 846 847 846 847 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 852 853 852 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 861 862 861 862 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 872 881 872 881 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 872 881 872 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g003"><bold>Figure 3B</bold></xref>
###xml 896 900 896 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Turner1">[21]</xref>
###xml 902 906 902 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 906 909 906 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1018 1019 1018 1019 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;</sup>
###xml 1022 1023 1022 1023 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;</sup>
###xml 1043 1044 1043 1044 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;</sup>
###xml 1048 1049 1048 1049 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1061 1062 1061 1062 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;</sup>
###xml 1066 1067 1066 1067 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;</sup>
###xml 1075 1084 1075 1084 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 1075 1084 1075 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g003"><bold>Figure 3A</bold></xref>
###xml 1127 1128 1127 1128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1131 1132 1131 1132 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1205 1212 1205 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 1212 1215 1212 1215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1222 1231 1222 1231 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 1222 1231 1222 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g003"><bold>Figure 3A</bold></xref>
###xml 1526 1530 1526 1530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Turner1">[21]</xref>
###xml 1555 1559 1555 1559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Turner1">[21]</xref>
###xml 1561 1565 1561 1565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Tarakhovsky1">[22]</xref>
###xml 1567 1571 1567 1571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 1571 1574 1571 1574 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1664 1665 1664 1665 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1689 1698 1689 1698 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 1689 1698 1689 1698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g003"><bold>Figure 3B</bold></xref>
###xml 1734 1741 1734 1741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 1746 1750 1746 1750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 1868 1872 1868 1872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 1890 1898 1890 1898 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3</bold>
###xml 1890 1898 1890 1898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g003"><bold>Figure 3</bold></xref>
###xml 2037 2044 2037 2044 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 430 434 <span type="species:ncbi:10090">mice</span>
###xml 588 592 <span type="species:ncbi:10090">mice</span>
###xml 747 751 <span type="species:ncbi:10090">mice</span>
###xml 910 914 <span type="species:ncbi:10090">mice</span>
###xml 1216 1220 <span type="species:ncbi:10090">mice</span>
###xml 1575 1579 <span type="species:ncbi:10090">mice</span>
In order to investigate the origin and ontology of those tumor cells, we decided to study the T-cell compartment in tumor-free animals. To this end, we performed histological and flow cytometry analyses of wild type, Vav1-/-, Rasgrf2-/- and Vav1-/-;Rasgrf2-/- animals that were six- to eight-week-old, an age period in which we had not detected any deaths or sickness sign in the animals. In addition, we focused our attention on mice that had survived up to a year of age and that, therefore, were categorized as "disease-free" animals in our first screening phase. In the case of young mice, we observed no obvious tumoral or pre-neoplasic manifestations in any of the animals analyzed (n = 20). Moreover, we found that wild type and Rasgrf2-/- mice exhibited the expected distribution of thymocyte subpopulations (Figure 3A) and of splenic CD3+, CD4+ and CD8+ T-cells (Figure 3B). As expected [21], Vav1-/- mice did show alterations in the percentage of thymocyte subpopulations due to a defective transition of CD4-CD8- cells from the CD44-CD25+ to the CD44-CD25- stage (Figure 3A). Although the relative percentages of CD4+CD8+ thymocytes did not change when compared with wild type counterparts and Rasgrf2-/- mice (Figure 3A), we did observe a reduction in the total numbers of production of these cells that resulted in lower levels of thymic cellularity (data not shown). This defect has been previously attributed to a defective positive selection that leads to enhanced mortality rates in this thymic subpopulation [21]. As previously reported [21], [22], Vav1-/- mice also manifested T-lymphopenia as inferred by the increased in the percentage of B220+ B-cells in the spleen (Figure 3B). The combined inactivation of the Rasgrf2 and Vav1 loci did not aggravate the thymocyte developmental/selection defects or the T-cell lymphopenia induced by the single Vav1 gene deficiency (Figure 3). Hence, these results indicate that young animals do not have neoplasic or pre-neoplasic manifestations and that the inactivation of the Rasgrf2 gene does not accentuate the already severe immune defects caused by the Vav1-deficiency.
###end p 24
###begin title 25
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
The Rasgrf2 gene deficiency does not affect the normal development of T-cells (A) or mature lymphocyte (B) cell numbers.
###end title 25
###begin p 26
###xml 212 213 212 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 223 224 223 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Bar graphs show the mean percentages of thymocyte (upper panels) and splenic lymphocyte (lower panels) subpopulations derived from animals of the indicated genotypes. Error bars represent the standard deviation (n = 5). *, P<0.01 compared to values obtained with wild type controls.
###end p 26
###begin p 27
###xml 218 227 218 227 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4A</bold>
###xml 218 227 218 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g004"><bold>Figure 4A</bold></xref>
###xml 383 384 383 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 386 397 386 397 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4A,B</bold>
###xml 386 397 386 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g004"><bold>Figure 4A,B</bold></xref>
###xml 420 429 420 429 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4A</bold>
###xml 420 429 420 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g004"><bold>Figure 4A</bold></xref>
###xml 501 510 501 510 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4C</bold>
###xml 501 510 501 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g004"><bold>Figure 4C</bold></xref>
###xml 582 583 582 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 617 628 617 628 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4A,C</bold>
###xml 617 628 617 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g004"><bold>Figure 4A,C</bold></xref>
###xml 813 822 813 822 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4A</bold>
###xml 813 822 813 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g004"><bold>Figure 4A</bold></xref>
###xml 902 906 902 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 906 909 906 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 929 930 917 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 941 945 929 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 945 948 933 936 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 949 956 937 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 956 959 944 947 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 979 980 955 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 998 1007 974 983 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4D</bold>
###xml 998 1007 974 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g004"><bold>Figure 4D</bold></xref>
###xml 1292 1293 1256 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1304 1311 1268 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 1311 1314 1275 1278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1334 1335 1286 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1348 1357 1300 1309 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4D</bold>
###xml 1348 1357 1300 1309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g004"><bold>Figure 4D</bold></xref>
###xml 807 811 <span type="species:ncbi:10090">mice</span>
###xml 1342 1346 <span type="species:ncbi:10090">mice</span>
###xml 1432 1437 <span type="species:ncbi:10090">mouse</span>
In contrast to the results with young animals, we observed that one-year-old, "tumor-free" animals displayed a high frequency of hyperplasic thymi with disrupted compartmentalization in cortical and medullary regions (Figure 4A; data not shown). As in the case of leukemia/lymphoma cells from the aforementioned tumor-bearing animals, these thymocytes expressed excess amounts of CD3+ (Figure 4A,B), were PCNA positive (Figure 4A), and showed a heterogeneous display of CD4 and CD8 surface molecules (Figure 4C and data not shown). However, we could not find any infiltration of CD3+ lymphoma cells in other tissues (Figure 4A,C). Furthermore, no signs of splenomegalia or lymphadenopathy could be detected in these "tumor-free" animals (data not shown). Kidneys, lungs and livers were also normal in these mice (Figure 4A). These thymic alterations were detected at very high rates in animals of both Vav1-/- (approximately85%, n = 14) and Vav1-/-;Rasgrf2-/- (approximately80%, n = 14) genotypes (Figure 4D). These results indicate that the T-cell leukemia/lymphomas found in these animals are of thymic origin. As in the case of invasive/metastatic leukemia/lymphomas, this thymus-restricted tumorigenesis was observed, although at lower rates, in one-year-old wild type (approximately17%, n = 25) and Rasgrf2-/- (approximately22%, n = 20) mice (Figure 4D), further suggesting that Vav1 accentuates the intrinsic tendency of this mouse strain to develop thymic lymphomas rather than promoting tumorigenesis in an autonomous fashion.
###end p 27
###begin title 28
###xml 27 30 27 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 23 30 23 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1<sup>&#8211;/&#8211;</sup></italic>
###xml 31 38 31 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 38 41 38 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 50 53 50 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
The lymphomas found in Vav1-/-;Rasgrf2-/- and Vav1-/- derive from the thymus.
###end title 28
###begin p 29
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 94 97 94 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 98 105 98 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 105 108 105 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 337 338 333 334 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 386 390 382 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 390 393 386 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 394 401 390 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 401 404 397 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 417 421 413 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 421 424 417 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 425 432 421 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 432 435 428 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 590 591 586 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 675 676 671 672 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 729 730 725 726 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 770 774 766 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 774 777 770 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 778 785 774 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 785 788 781 784 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 801 805 797 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 805 808 801 804 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 809 816 805 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 816 819 812 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1042 1043 1038 1039 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 109 114 <span type="species:ncbi:10090">mouse</span>
###xml 257 262 <span type="species:ncbi:10090">mouse</span>
###xml 436 441 <span type="species:ncbi:10090">mouse</span>
###xml 829 834 <span type="species:ncbi:10090">mouse</span>
###xml 1090 1094 <span type="species:ncbi:10090">mice</span>
(A) Hematoxylin/eosin, anti-CD3 and anti-PCNA staining of tissue sections obtained from a Vav1-/-;Rasgrf2-/- mouse with a thymus-localized lymphoma (panels 3-7 counting from left). As control, we stained thymus and spleen sections obtained from a wild type mouse (first and second panel from left, respectively). Scale bar, 100 microm. (B) Cell suspensions were obtained from a healthy Vav1-/-;Rasgrf2-/- (top) and a Vav1-/-;Rasgrf2-/- mouse with a thymus-localized tumor (bottom), stained with anti-CD3 antibodies and analyzed by flow cytometry. The red square highlights the abnormal, CD3+ positive cell population found in the thymus-localized tumor. The percentage of CD3+ cells in each case is indicated inside each panel. (C) Cell suspensions were obtained from a Vav1-/-;Rasgrf2+/+ (top) and a Vav1-/-;Rasgrf2-/- (bottom) mouse containing thymus-localized tumors, stained with anti-CD4 and anti-CD8 antibodies and analyzed by flow cytometry. Results similar to those shown in panels A-C were observed in 5 independent determinations. (D) Graph showing the percentage of one-year old mice of the indicated genotypes with thymus-localized tumors.
###end p 29
###begin title 30
###xml 65 73 <span type="species:ncbi:9606">Patients</span>
The Expression of RasGRF2 and Vav1 Is Altered in Very Restricted Patients Subgroups Affected by Hematopoietic Malignancies
###end title 30
###begin p 31
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 70 77 70 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 652 656 652 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 769 777 769 777 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5</bold>
###xml 769 790 769 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g005"><bold>Figure 5</bold>, upper panel</xref>
###xml 846 850 846 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 967 974 967 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 1042 1050 1042 1050 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5</bold>
###xml 1042 1063 1042 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g005"><bold>Figure 5</bold>, lower panel</xref>
###xml 1293 1301 1293 1301 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5</bold>
###xml 1293 1314 1293 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g005"><bold>Figure 5</bold>, lower panel</xref>
###xml 1372 1379 1372 1379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 1417 1425 1417 1425 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5</bold>
###xml 1417 1438 1417 1438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g005"><bold>Figure 5</bold>, lower panel</xref>
###xml 1782 1786 1782 1786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 1794 1801 1794 1801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 2049 2070 2049 2070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 2103 2107 2103 2107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 2244 2251 2244 2251 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 2244 2251 2244 2251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008229-t001"><bold>Table 1</bold></xref>
###xml 2386 2393 2386 2393 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 2386 2393 2386 2393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008229-t001"><bold>Table 1</bold></xref>
###xml 2495 2502 2495 2502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 2740 2744 2740 2744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 2749 2756 2749 2756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 2978 2999 2978 2999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 3306 3310 3306 3310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-MacDonald1">[23]</xref>
###xml 3331 3335 3331 3335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 3476 3485 3476 3485 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6A</bold>
###xml 3476 3485 3476 3485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g006"><bold>Figure 6A</bold></xref>
###xml 3487 3494 3487 3494 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 3487 3494 3487 3494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008229-t002"><bold>Table 2</bold></xref>
###xml 3527 3534 3527 3534 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 3527 3534 3527 3534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008229-t002"><bold>Table 2</bold></xref>
###xml 3565 3572 3565 3572 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 3565 3572 3565 3572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008229-t002"><bold>Table 2</bold></xref>
###xml 3655 3659 3655 3659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 3713 3720 3713 3720 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 3819 3828 3819 3828 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6B</bold>
###xml 3819 3828 3819 3828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g006"><bold>Figure 6B</bold></xref>
###xml 3830 3837 3830 3837 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 3</bold>
###xml 3830 3837 3830 3837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008229-t003"><bold>Table 3</bold></xref>
###xml 3968 3975 3968 3975 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 3</bold>
###xml 3968 3975 3968 3975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008229-t003"><bold>Table 3</bold></xref>
###xml 4046 4050 4046 4050 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 4055 4062 4055 4062 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 142 148 <span type="species:ncbi:9606">humans</span>
###xml 449 457 <span type="species:ncbi:9606">patients</span>
###xml 672 677 <span type="species:ncbi:9606">human</span>
###xml 1011 1016 <span type="species:ncbi:9606">human</span>
###xml 2815 2823 <span type="species:ncbi:9606">patients</span>
###xml 3167 3174 <span type="species:ncbi:9606">patient</span>
###xml 3424 3432 <span type="species:ncbi:9606">patients</span>
###xml 3608 3615 <span type="species:ncbi:9606">patient</span>
###xml 3682 3689 <span type="species:ncbi:9606">patient</span>
###xml 3741 3749 <span type="species:ncbi:9606">patients</span>
###xml 4244 4251 <span type="species:ncbi:9606">patient</span>
The above observations indicated that the deletion of the Vav1 and/or Rasgrf2 gene could play a role in the development of lymphoid tumors in humans. To get some insight into this possibility, we first resorted to a quantitative reverse transcription (RT)-PCR strategy to investigate the expression levels of both transcripts in a commercial cDNA collection containing samples from lymphocytes of healthy individuals and 42 independent samples from patients affected by lymphoma/leukemia. Those samples included several stages of lymphoma progression as well as a number of B-cell- and T-cell-derived tumors. We did not find any clear reduction in the VAV1 mRNA levels in human lymphoma samples when compared with those present in lymphocytes from healthy individuals (Figure 5, upper panel). On the contrary, we recorded a 30% of cases in which VAV1 mRNA levels were at least 2-fold higher than those found in normal lymphocytes. Instead, we detected a reduction in RASGRF2 transcript levels in 81% of all the human lymphoma cases analyzed (Figure 5, lower panel). Total elimination of the mRNAs for this protein was observed in a small lymphocytic lymphoma (stage I, sample 28), a peripheral T-cell lymphoma (stage II, sample 38), and a diffuse large B-cell lymphoma (stage IIE, sample 42) (Figure 5, lower panel). No statistically significant upregulated levels of the RASGRF2 mRNA were observed in these samples (Figure 5, lower panel). Since the number of samples available for the RT-PCR experiment was rather limited, we decided to expand these studies using in silico screenings with the microarray data present in the Oncomine site (). To this end, we first used a standard bioinformatics comparison tool available in that database to investigate whether the expression of VAV1 and/or RASGRF2 genes was deregulated in hematopoietic tumor cells relative to their normal cell counterparts. Since few data are available on T-cell lymphomas, we used microarray data derived from studies conducted on leukemia, lymphoma and myeloma samples (see Materials and Methods). These analyses indicated that VAV1 mRNA was overexpressed in chronic lymphocytic leukemia, diffuse large B-cell lymphoma and smoldering myeloma relative to control cells (Table 1). Instead, reduced levels of this transcript were observed in another chronic lymphocytic leukemia cohort and in hairy cell leukemia (Table 1). In contrast to the RT-PCR data, we found no significant variations in the expression levels of the RASGRF2 mRNA in the microarray data available at the Oncomine site, indicating that this gene is not commonly deregulated at least in the case of the hematopoietic tumors selected in this study. We next analyzed whether the expression levels of VAV1 and RASGRF2 genes were significantly altered in specific subgroups of patients affected of leukemia, lymphoma or myeloma. To this end, we used the cancer outlier profile analysis (COPA) method available at the Oncomine database (see Materials and Methods). This analysis allows the identification of small fraction of samples showing statistically significant variations in gene expression from the rest of the population patient cohort, thus bypassing the usual problem of the intrinsic heterogeneity present in all analyses based on clinically-derived tumors [23]. In the case of the VAV1 mRNA, we found a significant downmodulation in a small subgroup of samples derived from patients affected by diffuse large B-cell lymphoma (Figure 6A, Table 2), chronic lymphocytic leukemia (Table 2), and acute myeloid leukemia (Table 2). Instead, we could not detect any patient tumor subgroup showing upregulation of VAV1 relative to the total patient cohort. In the case of RASGRF2, we found groups of patients showing downmodulation of that gene in acute lymphoblastic leukemia (Figure 6B, Table 3). Upregulation was found in some cases of diffuse large B-cell lymphoma, acute myeloid leukemia and chronic myelogenous leukemia (Table 3). These results suggest that the changes in the expression profile of VAV1 and RASGRF2 genes are not a general event associated to the progression of hematopoietic tumors. Instead, such variation appears to be concentrated on small, although statistically significant patient subgroups.
###end p 31
###begin title 32
###xml 6 13 6 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human RASGRF2 transcript levels are downregulated in some malignant hemopaties when compared to normal lymphocytes.
###end title 32
###begin p 33
###xml 0 11 0 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Left panels</italic>
###xml 165 169 165 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 186 193 186 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 397 409 397 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Right panels</italic>
###xml 432 436 432 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 453 460 453 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 632 633 632 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Left panels, cDNA samples from six control lymphocyte samples were subjected to quantitative RT-PCR analysis to observe the variations in basal expression levels of VAV1 (top panel) and RASGRF2 (bottom panel) genes and to obtain the average expression values for each gene (which were given an arbitrary value of 1) to be used as reference in the subsequent RT-PCR experiments with tumor samples. Right panels, expression levels of VAV1 (top panel) and RASGRF2 (lower panel) mRNAs in lymphoma/leukemias (samples 7-48) of the indicated clinical stages by RT-PCR. The horizontal lane represents the mean value of the control samples. P values in this figure were estimated by comparing the groups of healthy and tumor samples. a.u., arbitrary units.
###end p 33
###begin title 34
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 80 87 80 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 12 19 <span type="species:ncbi:9606">patient</span>
Examples of patient subgroups showing reduced expression levels of VAV1 (A) and RASGRF2 (B) genes.
###end title 34
###begin p 35
###xml 123 124 123 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 165 166 165 166 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 205 206 205 206 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 246 247 246 247 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 287 288 287 288 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 337 338 337 338 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 401 422 401 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 614 622 614 622 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tables 2</bold>
###xml 614 622 614 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008229-t002"><bold>Tables 2</bold></xref>
###xml 627 628 627 628 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</bold>
###xml 627 628 627 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008229-t003"><bold>3</bold></xref>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Graphs show the variation in expression of those genes in samples obtained from patients in non-characterized tumors (NC) (A), B-cell non-Hodgkin's lymphoma (BNHL) (A), chronic lymphocytic leukemia (CLL) (B), diffuse large B-cell lymphoma (DBL) (A), B-cell acute lymphoblastic leukemia (B, upper panel) and acute lymphoblastic leukemia (B, lower panel). Outlier groups were identified as indicated in Materials and Methods. The respective CODA scores of each hit are indicated within each panel. The percentile of tumors showing the significant outlier values for the indicated gene is indicated on the right. See Tables 2 and 3 for further details. a.u., arbitrary units.
###end p 35
###begin title 36
###xml 42 46 42 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
Variation in the expression levels of the VAV1 mRNA between normal and tumor cells.
###end title 36
###begin p 37
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 74 81 74 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 255 256 255 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Searches were done using the following Oncomine parameters: gene: VAV1 or RASGRF2; analysis type: cancer vs normal analysis; dataset sizes: microarray data with a minimum of 75 independent samples; microarray platform: non restricted; gene rank, top 10%; P value</=0.001.
###end p 37
###begin title 38
###xml 42 46 42 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
Outlier analysis of the expression of the VAV1 mRNA in hematopoietic tumors.
###end title 38
###begin p 39
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 280 281 280 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 294 296 292 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;4</sup>
Searches were done using the following Oncomine parameters: gene: VAV1; analysis type: outlier analysis; cancer type: leukemia, lymphoma and myeloma; dataset sizes: microarray data with a minimum of 75 independent samples; microarray platform: non restricted; gene rank, top 10%; P value</=1x10-4; COPA value: less than -3.
###end p 39
###begin title 40
###xml 42 49 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
Outlier analysis of the expression of the RASGRF2 mRNA in hematopoietic tumors.
###end title 40
###begin p 41
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 280 281 280 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 294 296 292 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;4</sup>
Searches were done using the following Oncomine parameters: gene: VAV1; analysis type: outlier analysis; cancer type: leukemia, lymphoma and myeloma; dataset sizes: microarray data with a minimum of 75 independent samples; microarray platform: non restricted; gene rank, top 10%; P value</=1x10-4; COPA value: less than -3 for downregulated genes and higher than 3 for upregulated genes.
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 45 57 45 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1/Rasgrf2</italic>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 626 630 <span type="species:ncbi:10090">mice</span>
We have shown in this report that the double Vav1/Rasgrf2 gene deficiency favors the development and progression of lymphoblastic lymphoma-like tumors in mice. These tumors could be classified in two different subsets in function of their level of dissemination within the affected animal. A first subset was characterized by its exclusive intrathymic localization. The second subset showed that localization and, in addition, massive infiltrations in extra-thymic hematopoietic-tissues and non-hematopoietic tissues. This latter tumor subset was more aggressive in nature, leading to elevated mortality rates in the affected mice. Notwithstanding these differences in localization and lethality, we observed that these two tumor subsets shared many common biological features, including the expression of CD3 molecules, the heteroclite expression of CD4 and CD8 surface markers, the upregulation of proteins generally involved in proliferation (PCNA) and the lack of expression of TCR-induced markers (i.e., CD69). It is likely therefore that these two pathological subsets correspond to two different stages in lymphoma progression. For the sake of simplicity, we will refer to these two populations hereafter as "thymus-localized" and "widespread" lymphomas.
###end p 43
###begin p 44
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 13 20 13 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 122 126 122 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 478 482 478 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav2</italic>
###xml 482 485 482 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 487 491 487 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav3</italic>
###xml 491 494 491 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 498 502 498 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav2</italic>
###xml 502 505 502 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 506 510 506 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav3</italic>
###xml 510 513 510 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 568 575 568 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 756 760 756 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 771 778 771 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 1017 1024 1017 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 1455 1459 1455 1459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 1464 1471 1464 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 514 518 <span type="species:ncbi:10090">mice</span>
###xml 1682 1687 <span type="species:ncbi:10090">mouse</span>
The Vav1 and Rasgrf2 gene deficiencies seem to contribute differently to these two lymphoma stages. Thus, the loss of the Vav1 proto-oncogene increases preferentially the frequency of "thymus-localized" lymphomas in one-year-old animals and, to a much lower extent, the percentage of "widespread" tumors. This phenotype is specifically driven by the deficiency in this Vav family member, because we have not observed statistically significant increases in deaths/tumor rates in Vav2-/-, Vav3-/- or Vav2-/-;Vav3-/- mice when compared to control littermates. The single Rasgrf2 deficiency has only minor or no effects per se in promoting the widespread and thymus-localized subset of tumors, respectively. However, when combined with the inactivation of the Vav1 gene, the Rasgrf2 gene deficiency promotes a two-fold increase in the development of "widespread" lymphomas, shorter latency periods for the development of the disease, and enhanced mortality/sickness rates. These results suggest that the influence of the Rasgrf2 gene loss on lymphomagenesis is totally contingent on the prior disruption of Vav1 function in the T-cell compartment. Despite the above data, it is worth noting that the tumoral phenotype described here requires long latency periods to develop, is not fully penetrant, and is similar anatomopathologically and immunophenotypically to the lymphomas spontaneously arising in wild type animals. These observations indicate that the Vav1 and Rasgrf2 gene deficiencies do not trigger single-handedly transformation but, rather, may offer an extra selective advantage for the tumorigenic events that trigger the fortuitous development of lymphomas in the B10.BR mouse strain used in this study.
###end p 44
###begin p 45
###xml 207 211 207 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Bustelo1">[24]</xref>
###xml 524 528 524 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Tybulewicz1">[25]</xref>
###xml 647 651 647 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Tybulewicz1">[25]</xref>
###xml 653 657 653 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Saveliev1">[26]</xref>
###xml 940 944 940 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 944 947 944 947 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1507 1510 1507 1510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav</italic>
###xml 1510 1513 1510 1513 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1859 1860 1856 1857 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;</sup>
###xml 1926 1930 1923 1927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Dumont1">[27]</xref>
###xml 1992 1996 1989 1993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Grabher1">[28]</xref>
###xml 2209 2213 2206 2210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 2213 2216 2210 2213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 2221 2225 2218 2222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 2225 2228 2222 2225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 2229 2236 2226 2233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 2236 2239 2233 2236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 2245 2249 2242 2246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Cleverley1">[29]</xref>
###xml 948 952 <span type="species:ncbi:10090">mice</span>
###xml 1158 1163 <span type="species:ncbi:10090">mouse</span>
###xml 1963 1968 <span type="species:ncbi:9606">human</span>
###xml 2240 2244 <span type="species:ncbi:10090">mice</span>
What is the basis of this enhanced tumorigenesis? In the case of Vav1, the results reported here are totally at odds with the known functions of this protein in cell signaling, proliferation and oncogenesis [24]. Furthermore, Vav1 is also important in the T-cell compartment for the assembly of optimal signaling responses directly or indirectly related to cell growth, such as specific T-cell developmental transitions, thymocyte selection steps, and proliferative responses to antigens in the case of mature T-lymphocytes [25]. Such functions rely on the activation of Rac1, the Ras route and, in some cases, catalytically-independent functions [25], [26]. Given the implication of Vav1 in positive and negative TCR selection events in thymocytes, it could be speculated that the perturbation of thymic development or, alternatively, the lack of elimination of immature T-cells carrying tumorigenic rearrangements of antigen receptors in Vav1-/- mice could create a pool of tumorigenic events that may eventually increase lymphoma development rates in those animals. We do not support such possibility, since we are not aware of any report indicating that mouse strains with defective selection defects in the thymus are prone to tumorigenesis in the T-cell compartment. On the other hand, it could be also argued that the deficient signaling derived from the Vav1 deficiency will favor other signaling routes in specific thymocyte subsets or, alternatively, place an additional pressure on pre-neoplasic Vav-/- thymocytes that could create a Darwinian field to promote the selection of highly mitogenic thymocytes carrying pro-tumorigenic mutations in other signal transduction elements. In this context, it is worth mentioning that Tybulewicz's group has shown recently that deficiencies in either Rac or Vav family genes may favor the survival of TCRbeta- thymocytes due to hyperactivation of the Notch signaling pathway [27], a route usually deregulated in human lymphoblastic leukemia [28]. Cantrell's group has also shown that the elimination in thymocytes of RhoA function, a GTPase activated by Vav family proteins, leads to a lymphoblastic lymphoma very similar to the disseminated tumors found in Vav1-/- and Vav1-/-;Rasgrf2-/- mice [29]. These data suggest that the role of Vav1 in thymic lymphomagenesis could be linked to dysfunctions in its direct downstream targets Rac1 and/or RhoA.
###end p 45
###begin p 46
###xml 74 78 74 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Ruiz1">[18]</xref>
###xml 290 297 290 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 343 347 343 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Qiu1">[12]</xref>
###xml 348 352 348 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Jacinto1">[15]</xref>
###xml 499 503 499 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Jacinto1">[15]</xref>
###xml 677 684 677 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 753 757 753 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 1201 1208 1201 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 1436 1440 1436 1440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Ruiz1">[18]</xref>
###xml 1483 1487 1483 1487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 1487 1490 1487 1490 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1491 1498 1491 1498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 1498 1501 1498 1501 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1624 1628 1624 1628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 1633 1640 1633 1640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
RasGRF2 promotes, similarly to Vav1, positive responses in mature T-cells [18]. However, unlike the case of Vav1, there is evidence indicating that it may also exert some tumor-suppressor activities. Thus, several reports have shown decreased expression and/or increased methylation of the Rasgrf2 gene in cancer cell lines and primary tumors [12]-[15]. Moreover, it has been demonstrated that the overexpression of RasGRF2 negatively affects the transforming properties of a colon cancer cell line [15]. Despite these observations, we do not consider that the putative tumor suppressor activity of RasGRF2 is a plausible explanation for the results reported here, because the Rasgrf2 deficiency only contributes to tumorigenesis when combined with the Vav1 proto-oncogene loss. It is possible therefore that this cooperativity in lymphomagenesis promotion is just another reflection of the synergistic interactions occurring between the Vav1- and the RasGRF2-dependent pathways in normal T-cells. Hence, and similarly to the observations reported here, we have observed before that the endogenous RasGRF2 plays important, but subsidiary roles to the Vav1 route, in T-cell signaling. For example, the Rasgrf2 gene deficiency does not affect the proliferation and blast formation of TCR-stimulated T-lymphocytes but, instead, it aggravates the already defective proliferative responses of Vav1-deficient T-cells to TCR-dependent signals [18]. Since the lack of CD69 expression in the Vav1-/-;Rasgrf2-/- tumor cells suggests that their growth is mediated by TCR-independent mechanisms, the synergistic interaction between the Vav1 and Rasgrf2 gene deficiencies will probably need the alteration of TCR-independent routes rather than the canonical TCR downstream pathways for this hypothesis to be correct. The discrimination of all these regulatory possibilities will have wait to the identification of the signaling deficiency promoting the tumorigenesis in Vav1-deficient lymphocytes.
###end p 46
###begin p 47
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 30 37 30 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 757 761 757 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 766 773 766 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
###xml 178 183 <span type="species:ncbi:9606">human</span>
###xml 751 756 <span type="species:ncbi:9606">human</span>
###xml 931 938 <span type="species:ncbi:9606">patient</span>
The observation that Vav1 and Rasgrf2 gene deficiencies promote enhanced tumorigenic rates in mice led us to verify whether the expression of these genes could be deregulated in human hematological tumors. Unfortunately, there are no many data available on T-cell lymphomas/leukemias, so we could not directly address changes in the expression of these two genes in these cancer subtypes. In order to get a general view of the expression of these two genes in hematological tumors, we have carried out expression studies by quantitative RT-PCR in a limited collection of hematopoietic tumors and, in addition, by in silico profiling using microarray data publicly available at the Oncomine database. The take home message of these studies is that the human VAV1 and RASGRF2 genes do not show a consistent and generalizable change pattern in hematopoietic tumors such as lymphomas, leukemias or myelomas. However, we did find small patient subgroups affected by some of those pathologies that show statistically significant upregulation/downmodulations of these two transcripts. Interestingly, we did not detect a coincidence in the change patterns of those two genes in the tumors analyzed so, if they contribute to the tumorigenesis, they must do so in cooperation with other mutations. It will be really important in the future to obtain a large group of T-cell lymphoma/leukemia samples in order to assess the specific implication of Vav1 and RasGRF2 in this tumorigenic context.
###end p 47
###begin p 48
###xml 479 482 479 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Sahai1">[2]</xref>
###xml 484 488 484 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-PrietoSanchez1">[30]</xref>
###xml 489 493 489 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-GomezdelPulgar1">[35]</xref>
###xml 747 754 747 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 466 471 <span type="species:ncbi:9606">human</span>
###xml 715 723 <span type="species:ncbi:9606">patients</span>
###xml 1009 1014 <span type="species:ncbi:9606">human</span>
###xml 1015 1023 <span type="species:ncbi:9606">patients</span>
Not withstanding the actual role of these two proteins in T-cell lymphomas/leukemias, our observations do have some interest from a therapeutical point of view. Thus, it has been always assumed that the inactivation of the function of Vav and Rho/Rac family proteins could be of interest to treat cancer cells. The interest on this possibility has been also fueled by observations indicating that Vav and Rho/Rac family members are overexpressed in certain types of human tumors [2], [30]-[35]. However, our present data puts a note of caution on those possible avenues, since they indicate that the blockage of Vav family-dependent signaling could be highly counterproductive in the case of lymphoblastic lymphoma patients with reduced levels of RASGRF2 gene expression in tumor cells. Hence, it will be important in the future to evaluate the beneficial/adverse effect of Vav family-directed therapeutics in different tumor types before initiating the search for Vav-specific drugs and clinical trials with human patients.
###end p 48
###begin title 49
Materials and Methods
###end title 49
###begin title 50
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse Strains
###end title 50
###begin p 51
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1<sup>&#8211;/&#8211;</sup></italic>
###xml 9 16 9 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav1</italic>
###xml 25 28 25 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 29 36 29 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rasgrf2</italic>
###xml 36 39 36 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav2</italic>
###xml 45 48 45 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav3</italic>
###xml 54 57 54 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 62 66 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav2</italic>
###xml 66 69 66 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vav3</italic>
###xml 74 77 74 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 114 118 114 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Ruiz1">[18]</xref>
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Doody1">[36]</xref>
###xml 125 129 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Sauzeau2">[38]</xref>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
Vav1-/-, Rasgrf2-/-, Vav1-/-;Rasgrf2-/-, Vav2-/-, Vav3-/- and Vav2-/-;Vav3-/- mice have been previously described [18], [36]-[38]. All mice used in these experiments were bred and maintained in the SPF Animal Facility of the University of Salamanca using 12-hour light/darkcycles. All animal-based experiments were approved by the Animal Use and Welfare Committees of the CSIC and University of Salamanca as well as by the Bioethics Comittee of the University of Salamanca. These approvals include review of the experimental protocols to be used in the animal work and, in addition, a description of the measures taken to avoid animal discomfort or pain.
###end p 51
###begin title 52
Histological and Immunohistochemical Analyses
###end title 52
###begin p 53
###xml 223 228 <span type="species:ncbi:10090">mouse</span>
###xml 370 381 <span type="species:ncbi:3704">horseradish</span>
###xml 428 433 <span type="species:ncbi:10090">mouse</span>
Selected tissues were fixed in a buffered 4% formaldehyde solution for 48 h and paraffin-embedded. Sections were cut, stained with either hematoxylin/eosin (Sigma) and processed for immunohistochemistry using antibodies to mouse CD3 (clone F7.2.38, 1:200 dilution, Dako) and PCNA (clone PC10, 1:100 dilution, Cell Signaling). Immunoreactive signals were developed using horseradish peroxidase-conjugated secondary antibodies to mouse immunoglobulins (GE Healthcare).
###end p 53
###begin title 54
Flow Cytometry Analysis
###end title 54
###begin p 55
###xml 424 425 420 421 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1225 1229 1221 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008229-Ruiz1">[18]</xref>
Single cell suspensions were prepared by homogenization of tissues with the aid of 50 microm filters (Falcon). In the case of bone marrow cells, phosphate-buffered saline solution was flushed gently into the medullar cavity of isolated femoral bones and resulting cell suspensions washed using cycles of low-speed centrifugation and resuspension in phosphate-buffered saline solution. After erythrocyte lysis using 0.17 M NH4Cl, lymphocytes were stained with appropriate combinations of fluorescein-labeled anti-CD4, phycoerythrin-labeled anti-CD3, and allophycocyanin-labeled anti-CD8 antibodies. For the determination of thymic populations and splenic lymphocytes, cell suspensions were stained with antibodies to surface markers using appropriate combinations of fluorescein-labeled anti-CD4 and anti-CD44 antibodies, peridinin chlorophyll protein-labeled anti-CD4, anti-CD25 and anti-CD69 antibodies and allophycocyanin-labeled anti-CD4, anti-CD8 and anti-B220 antibodies. All the antibodies were obtained from BD Biosciences. Flow cytometry analyses were conducted using a FACSCalibur system (BD Biosciences) and analyzed using the Cell Quest (BD Biosciences), BD Paint-a-Gate (BD Biosciences), and WinMDI 2.8 softwares [18].
###end p 55
###begin title 56
Quantitative RT-PCR Analysis
###end title 56
###begin p 57
###xml 201 205 201 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 210 217 210 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 507 510 507 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
###xml 516 518 514 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 619 623 617 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 625 632 623 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 637 642 635 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 972 977 970 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 120 123 <span type="species:ncbi:9685">Cat</span>
###xml 613 618 <span type="species:ncbi:9606">human</span>
A panel of cDNA samples obtained from normal and tumoral lymphoid samples (TissueScan Lymphoma Tissue qPCR Array I (2), Cat. Number LYRT101, Origene Technologies) was used to analyze the expression of VAV1 and RASGRF2 transcripts in different subsets of lymphomas. A detailed description of the lymphoma samples contained in that array can be obtained in the web of the commercial supplier (. aspx). Quantitative PCR reactions were performed in the IQ5 Real-Time PCR detection system (BioRad) using the SYBR(R) GreenTM two-step qRT-PCR kit (Invitrogen). Sequences of the primers used for the amplification of the human VAV1, RASGRF2 and GAPDH are available upon request. As comparative control, we used the average of the expression of those genes in six independent wild type lymphoid tissues (which was given an arbitrary value of 1). The expression values obtained in each experimental sample were also normalized taking into consideration the expression levels of the GAPDH gene. Quantitative PCR analyses were performed in three independent replicas that yielded similar results.
###end p 57
###begin title 58
In Silico Analysis of the Expression of VAV1 and RASGRF Family Members in Hematological Tumors
###end title 58
###begin p 59
###xml 218 222 218 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 226 233 226 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 368 369 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 519 523 517 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAV1</italic>
###xml 527 534 525 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASGRF2</italic>
###xml 714 715 712 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 728 730 724 726 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;4</sup>
To carry out the comparative analysis between normal and tumor cells, we used the "differential cancer versus normal analysis" tool available at the Oncomine database (). The settings used for the searches were: gene: VAV1 or RASGRF2; dataset size: microarray data containing a minimum of 75 independent samples; microarray platform: unrestricted; gene rank: top 10%; P value</=0.001. CODA analysis were done using the "outlier analysis" tool present in the Oncomine database. The settings for the searches were: gene: VAV1 or RASGRF2; cancer type: leukemia, lymphoma and myeloma; dataset size: microarray data containing a minimum of 75 independent samples; microarray platform: unrestricted; gene rank: top 10%; P value</=1x10-4; COPA value: less than -3 or more than 3 for the downregulated and upregulated outliers, respectively.
###end p 59
###begin title 60
Statistical Analysis
###end title 60
###begin p 61
###xml 40 49 40 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 40 49 40 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g001"><bold>Figure 1A</bold></xref>
###xml 74 82 74 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6</bold>
###xml 74 82 74 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008229-g006"><bold>Figure 6</bold></xref>
###xml 87 95 87 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tables 2</bold>
###xml 87 95 87 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008229-t002"><bold>Tables 2</bold></xref>
###xml 96 97 96 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</bold>
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008229-t003"><bold>3</bold></xref>
###xml 116 117 116 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
We used the logrank/Mantel-Cox test for Figure 1A, the CODA algorithm for Figure 6 and Tables 2-3 and the Student's t-test for the rest of analyses.
###end p 61
###begin p 62
We thank Maite Blazquez, Teresa Iglesias, Mauricio Menacho-Marquez, and Javier Tamame for technical help.
###end p 62
###begin title 63
References
###end title 63
###begin article-title 64
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human RAS superfamily proteins and related GTPases.
###end article-title 64
###begin article-title 65
RHO-GTPases and cancer.
###end article-title 65
###begin article-title 66
The role of Rho GTPases in disease development.
###end article-title 66
###begin article-title 67
Ras and Rho GTPases: a family reunion.
###end article-title 67
###begin article-title 68
Function and regulation of ras.
###end article-title 68
###begin article-title 69
ras genes.
###end article-title 69
###begin article-title 70
GEFs and GAPs: critical elements in the control of small G proteins.
###end article-title 70
###begin article-title 71
RhoGDIs revisited: novel roles in Rho regulation.
###end article-title 71
###begin article-title 72
GDIs: central regulatory molecules in Rho GTPase activation.
###end article-title 72
###begin article-title 73
Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling.
###end article-title 73
###begin article-title 74
RhoGDI is required for Cdc42-mediated cellular transformation.
###end article-title 74
###begin article-title 75
###xml 79 82 <span type="species:ncbi:10116">rat</span>
Allelic imbalance and altered expression of genes in chromosome 2q11-2q16 from rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
###end article-title 75
###begin article-title 76
###xml 83 88 <span type="species:ncbi:9606">human</span>
Identification of 27 5' CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers.
###end article-title 76
###begin article-title 77
###xml 47 52 <span type="species:ncbi:9606">human</span>
Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.
###end article-title 77
###begin article-title 78
Discovery of epigenetically silenced genes by methylated DNA immunoprecipitation in colon cancer cells.
###end article-title 78
###begin article-title 79
###xml 13 18 <span type="species:ncbi:9606">human</span>
vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells.
###end article-title 79
###begin article-title 80
Regulation of RasGRP via a phorbol ester-responsive C1 domain.
###end article-title 80
###begin article-title 81
RasGRF2, a guanosine nucleotide exchange factor for Ras GTPases, participates in T-cell signaling responses.
###end article-title 81
###begin article-title 82
PCNA, the maestro of the replication fork.
###end article-title 82
###begin article-title 83
CD69 is an immunoregulatory molecule induced following activation.
###end article-title 83
###begin article-title 84
A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes.
###end article-title 84
###begin article-title 85
Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav.
###end article-title 85
###begin article-title 86
COPA-cancer outlier profile analysis.
###end article-title 86
###begin article-title 87
Regulatory and signaling properties of the Vav family.
###end article-title 87
###begin article-title 88
Vav1: a key signal transducer downstream of the TCR.
###end article-title 88
###begin article-title 89
Lymphocyte signaling: beyond knockouts.
###end article-title 89
###begin article-title 90
Rac GTPases play critical roles in early T cell development.
###end article-title 90
###begin article-title 91
Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia.
###end article-title 91
###begin article-title 92
Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma.
###end article-title 92
###begin article-title 93
Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q.
###end article-title 93
###begin article-title 94
Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis.
###end article-title 94
###begin article-title 95
###xml 91 96 <span type="species:ncbi:9606">human</span>
Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.
###end article-title 95
###begin article-title 96
Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
###end article-title 96
###begin article-title 97
###xml 84 89 <span type="species:ncbi:9606">human</span>
Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer.
###end article-title 97
###begin article-title 98
Rho GTPase expression in tumourigenesis: evidence for a significant link.
###end article-title 98
###begin article-title 99
Signal transduction through Vav-2 participates in humoral immune responses and B cell maturation.
###end article-title 99
###begin article-title 100
###xml 77 81 <span type="species:ncbi:10090">mice</span>
Loss of Vav2 proto-oncogene causes tachycardia and cardiovascular disease in mice.
###end article-title 100
###begin article-title 101
Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction.
###end article-title 101
###begin article-title 102
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.
###end article-title 102
###begin article-title 103
Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status.
###end article-title 103
###begin article-title 104
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
###end article-title 104
###begin article-title 105
###xml 46 51 <span type="species:ncbi:9606">human</span>
Reverse engineering of regulatory networks in human B cells.
###end article-title 105
###begin article-title 106
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
###end article-title 106
###begin article-title 107
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.
###end article-title 107
###begin article-title 108
Molecular diagnosis of Burkitt's lymphoma.
###end article-title 108
###begin article-title 109
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
###end article-title 109
###begin article-title 110
Gene expression changes associated with progression and response in chronic myeloid leukemia.
###end article-title 110
###begin article-title 111
Classification of pediatric acute lymphoblastic leukemia by gene expression profiling.
###end article-title 111
###begin article-title 112
###xml 123 131 <span type="species:ncbi:9606">Children</span>
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected].
###end article-title 112
###begin p 113
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 113
###begin p 114
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: X.R.B. work is supported by grants from the NIH (5R01-CA73735-13), the Spanish Ministry of Science and Innovation (SAF2006-01789), the Red Tematica de Investigacion Cooperativa en Cancer (RD06/0020/0001), and the Castilla y Leon Autonomous Government (SA053A05 and GR97). S.R. was supported by a Juan de la Cierva postdoctoral position funded by the Spanish Ministry of Science and Innovation. The activities of the Centro de Investigacion del Cancer are partially supported by the Ramon Areces Foundation and by the Foundation for Cancer Research at the University of Salamanca. X.R.B. lab has been recognized as a Consolidated Cancer Research Group by the Spanish Association against Cancer. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 114

